
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (07): 844-852.DOI: 10.12114/j.issn.1007-9572.2023.0448
Special Issue: 消化系统疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2023-08-03
Revised:2024-03-25
Published:2025-03-05
Online:2025-01-23
Contact:
LI Shengmian
通讯作者:
李胜棉
作者简介:作者贡献:
宋芬芬进行研究方案的构思与设计、病例资料的收集与整理,统计学分析,撰写论文,绘制表格及论文的修订;李胜棉进行研究的可行性分析和文章的质量控制及审校,对文章整体负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0448
| 项目 | 患者数 |
|---|---|
| 治疗线数 | |
| 1线 | 39(55.7) |
| 2线 | 7(10.0) |
| ≥3线 | 1(1.4) |
| 新辅助治疗 | 23(32.9) |
| 治疗方案 | |
| 卡瑞利珠单抗单药 | 4(5.7) |
| 卡瑞利珠单抗联合化疗 | 63(90.0) |
| 白蛋白结合型紫杉醇+铂 | 36(51.4) |
| 紫杉醇+铂 | 7(10.0) |
| 多西他赛+铂 | 7(10.0) |
| 白蛋白结合型紫杉醇 | 4(7.1) |
| 氟尿嘧啶+铂 | 3(4.3) |
| 氟尿嘧啶 | 2(2.9) |
| 替吉奥 | 1(1.4) |
| 白蛋白结合型紫杉醇+替吉奥 | 1(1.4) |
| 替吉奥+铂 | 1(1.4) |
| 依托泊苷+铂 | 1(1.4) |
| 卡瑞利珠单抗联合化疗及靶向治疗 | 3(4.3) |
| 氟尿嘧啶+阿帕替尼 | 1(1.4) |
| 依托泊苷+铂+阿帕替尼 | 1(1.4) |
| 氟尿嘧啶+铂+阿帕替尼 | 1(1.4) |
| 放射治疗 | |
| 联合 | 58(82.9) |
| 不联合 | 12(17.1) |
Table 1 Treatment patterns of Camrelizumab
| 项目 | 患者数 |
|---|---|
| 治疗线数 | |
| 1线 | 39(55.7) |
| 2线 | 7(10.0) |
| ≥3线 | 1(1.4) |
| 新辅助治疗 | 23(32.9) |
| 治疗方案 | |
| 卡瑞利珠单抗单药 | 4(5.7) |
| 卡瑞利珠单抗联合化疗 | 63(90.0) |
| 白蛋白结合型紫杉醇+铂 | 36(51.4) |
| 紫杉醇+铂 | 7(10.0) |
| 多西他赛+铂 | 7(10.0) |
| 白蛋白结合型紫杉醇 | 4(7.1) |
| 氟尿嘧啶+铂 | 3(4.3) |
| 氟尿嘧啶 | 2(2.9) |
| 替吉奥 | 1(1.4) |
| 白蛋白结合型紫杉醇+替吉奥 | 1(1.4) |
| 替吉奥+铂 | 1(1.4) |
| 依托泊苷+铂 | 1(1.4) |
| 卡瑞利珠单抗联合化疗及靶向治疗 | 3(4.3) |
| 氟尿嘧啶+阿帕替尼 | 1(1.4) |
| 依托泊苷+铂+阿帕替尼 | 1(1.4) |
| 氟尿嘧啶+铂+阿帕替尼 | 1(1.4) |
| 放射治疗 | |
| 联合 | 58(82.9) |
| 不联合 | 12(17.1) |
| 不良反应 | 所有级别 | 1~2级 | 3级 | 4级 |
|---|---|---|---|---|
| RCCEP | 46(65.7) | 46(65.7) | 0 | 0 |
| 恶心/呕吐 | 30(42.8) | 30(42.8) | 0 | 0 |
| 贫血 | 26(37.1) | 26(37.1) | 0 | 0 |
| 乏力 | 26(37.1) | 26(37.1) | 0 | 0 |
| 脱发 | 24(34.2) | 24(34.2) | 0 | 0 |
| 白细胞减少 | 20(28.6) | 16(22.9) | 3(4.3) | 1(1.4) |
| 血小板减少 | 17(24.3) | 14(20.0) | 2(2.9) | 1(1.4) |
| 中性粒细胞减少 | 15(21.4) | 11(15.7) | 2(2.9) | 2(2.9) |
| 甲状腺功能亢进症 | 13(18.6) | 13(18.6) | 0 | 0 |
| 丙氨酸氨基转移酶升高 | 8(11.4) | 8(11.4) | 0 | 0 |
| 天冬氨酸氨基转移酶升高 | 7(10.0) | 7(10.0) | 0 | 0 |
| 皮疹/瘙痒 | 6(8.5) | 5(7.1) | 1(1.4) | 0 |
| 胆红素升高 | 5(7.1) | 5(7.1) | 0 | 0 |
| 腹泻 | 4(5.7) | 4(5.7) | 0 | 0 |
| 肺炎 | 4(5.7) | 3(4.3) | 1(1.4) | 0 |
| 肌酐升高 | 2(2.9) | 2(2.9) | 0 | 0 |
| 甲状腺功能减退 | 2(2.9) | 2(2.9) | 0 | 0 |
| 血糖升高 | 2(2.9) | 2(2.9) | 0 | 0 |
| 心肌炎 | 1(1.4) | 1(1.4) | 1(1.4) | 0 |
| 肾炎 | 1(1.4) | 0 | 0 | 1(1.4) |
| 心律失常 | 1(1.4) | 1(1.4) | 0 | 0 |
| 蛋白尿 | 1(1.4) | 1(1.4) | 0 | 0 |
| 关节炎 | 1(1.4) | 1(1.4) | 0 | 0 |
| 肾上腺功能减退 | 1(1.4) | 1(1.4) | 0 | 0 |
| 输注相关反应 | 1(1.4) | 1(1.4) | 0 | 0 |
Table 2 Treatment related adverse events
| 不良反应 | 所有级别 | 1~2级 | 3级 | 4级 |
|---|---|---|---|---|
| RCCEP | 46(65.7) | 46(65.7) | 0 | 0 |
| 恶心/呕吐 | 30(42.8) | 30(42.8) | 0 | 0 |
| 贫血 | 26(37.1) | 26(37.1) | 0 | 0 |
| 乏力 | 26(37.1) | 26(37.1) | 0 | 0 |
| 脱发 | 24(34.2) | 24(34.2) | 0 | 0 |
| 白细胞减少 | 20(28.6) | 16(22.9) | 3(4.3) | 1(1.4) |
| 血小板减少 | 17(24.3) | 14(20.0) | 2(2.9) | 1(1.4) |
| 中性粒细胞减少 | 15(21.4) | 11(15.7) | 2(2.9) | 2(2.9) |
| 甲状腺功能亢进症 | 13(18.6) | 13(18.6) | 0 | 0 |
| 丙氨酸氨基转移酶升高 | 8(11.4) | 8(11.4) | 0 | 0 |
| 天冬氨酸氨基转移酶升高 | 7(10.0) | 7(10.0) | 0 | 0 |
| 皮疹/瘙痒 | 6(8.5) | 5(7.1) | 1(1.4) | 0 |
| 胆红素升高 | 5(7.1) | 5(7.1) | 0 | 0 |
| 腹泻 | 4(5.7) | 4(5.7) | 0 | 0 |
| 肺炎 | 4(5.7) | 3(4.3) | 1(1.4) | 0 |
| 肌酐升高 | 2(2.9) | 2(2.9) | 0 | 0 |
| 甲状腺功能减退 | 2(2.9) | 2(2.9) | 0 | 0 |
| 血糖升高 | 2(2.9) | 2(2.9) | 0 | 0 |
| 心肌炎 | 1(1.4) | 1(1.4) | 1(1.4) | 0 |
| 肾炎 | 1(1.4) | 0 | 0 | 1(1.4) |
| 心律失常 | 1(1.4) | 1(1.4) | 0 | 0 |
| 蛋白尿 | 1(1.4) | 1(1.4) | 0 | 0 |
| 关节炎 | 1(1.4) | 1(1.4) | 0 | 0 |
| 肾上腺功能减退 | 1(1.4) | 1(1.4) | 0 | 0 |
| 输注相关反应 | 1(1.4) | 1(1.4) | 0 | 0 |
| 组别 | 例数 | 最佳疗效 | ORR | DCR | |||
|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | ||||
| RCCEP组 | 46 | 9(19.6) | 26(56.5) | 10(21.7) | 1(2.2) | 35(76.1) | 45(97.8) |
| 无RCCEP组 | 24 | 2(8.3) | 9(35.7) | 7(29.2) | 6(25.0) | 11(45.8) | 18(75.0) |
| χ2值 | 10.983 | 6.407a | 6.770 | ||||
| P值 | 0.012 | 0.011 | 0.009 | ||||
Table 3 The relationship between RCCEP and the efficacy of Camrelizumab
| 组别 | 例数 | 最佳疗效 | ORR | DCR | |||
|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | ||||
| RCCEP组 | 46 | 9(19.6) | 26(56.5) | 10(21.7) | 1(2.2) | 35(76.1) | 45(97.8) |
| 无RCCEP组 | 24 | 2(8.3) | 9(35.7) | 7(29.2) | 6(25.0) | 11(45.8) | 18(75.0) |
| χ2值 | 10.983 | 6.407a | 6.770 | ||||
| P值 | 0.012 | 0.011 | 0.009 | ||||
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
College of American Pathologists. Cancer protocol templates [A/OL]. (2021-06-11)[2023-02-15].
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer:A randomised controlled trial[J]. Lancet,2002,359(9319):1727-1733. DOI:10.1016/S0140-6736(02)08651-8.
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
苏婷凤,陈俊强,林宇,等. 中晚期食管鳞癌紫杉醇联合不同铂类药加IMRT的预后分析[J]. 中华放射肿瘤学杂志,2017,26(1):35-40. DOI:10.3760/cma.j.issn.1004-4221.2017.01.007.
|
| [31] |
文兵,吴国俊,明波. 紫杉醇联合不同铂类术前化学治疗食管鳞癌疗效分析[J]. 中国药业,2017,26(19):62-65. DOI:10.3969/j.issn.1006-4931.2017.19.017.
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [1] | ZHANG Chu, KONG Weimin, DENG Boer. Advances in Pharmacological Treatment of Recurrent or Metastatic Cervical Cancer [J]. Chinese General Practice, 2026, 29(32): 4815-4820. |
| [2] | YAO Ying, DUAN Liran, HAN Dianli, MIAO Tianxin, CHEN Ke, ZHANG Lan, GU Haiyue. Construction and Application of Fall Prevention Continuous Intervention Program for Young-old Patients [J]. Chinese General Practice, 2026, 29(30): 4415-4423. |
| [3] | WANG Wei, YU Fei, YAN Xiaohong. Application and Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure with Different Etiologies: Evidence from Ischemic and Non-ischemic Heart Failure [J]. Chinese General Practice, 2026, 29(27): 3976-3984. |
| [4] | DU Ruofang, CAO Yang, LIU Dianna, ZHANG Qixin, WANG Xiaofan, SHI Enze, ZHANG Yuxin, LI Quanwang. A 10-Year Clinical Review of Raw Pinelliae Rhizoma in Tumor Treatment: Usage Patterns and Safety Evaluation [J]. Chinese General Practice, 2026, 29(27): 3995-4003. |
| [5] | CHEN Jingjing, BAI Xinyuan, SHA Huizi, SUN Yi, NI Jiayao, TONG Fan, ZOU Lu, MENG Fanyan, DU Juan. Analysis of the Efficacy and Safety of Gemcitabine plus S-1 Regimen versus S-1 Combined with Oxaliplatin and Irinotecan Regimen as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma [J]. Chinese General Practice, 2026, 29(26): 3767-3773. |
| [6] | SI Xinying, MA Wenyuan, GUO Zhixun, QI Shuo, CHEN Xiaoheng, LI Zhe, LI Lu, DING Zhiguo. Preliminary Development of a Syndrome Efficacy Evaluation Scale for Hypothyroidism Secondary to Hashimoto's Thyroiditis: Based on Expert Consultation and Clinical Investigation [J]. Chinese General Practice, 2026, 29(24): 3528-3537. |
| [7] | LI Xueni, LIU Gejing, LIU Yongming. Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis [J]. Chinese General Practice, 2026, 29(24): 3509-3519. |
| [8] | LI Yutong, ZHAO Danting, JIANG Feng, WANG Yanna, LIU Yizong, LIANG Wenjuan, LU Jiahai. Systematic Review and Meta-analysis of the Efficacy and Safety of mRNA and Recombinant Protein Subunit Vaccines Against Respiratory Syncytial Virus [J]. Chinese General Practice, 2026, 29(19): 2744-2752. |
| [9] | YANG Haifei, SUN Wu, WU Cheng, REN Wei, LI Rutian. Analysis of Predictors for Immune-related Adverse Events and the Correlation with Efficacy in Progressive Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2026, 29(06): 710-717. |
| [10] | ZHANG Yanjing, ZHOU Chunhua, LI Xiaodong, LIU Yan, WANG Jing, YU Jing. Study on the Clinical Value of a Risk Prediction Model for Venlafaxine Plasma Concentration Exceeding the Safety Threshold [J]. Chinese General Practice, 2026, 29(06): 777-782. |
| [11] | ZHANG Ling, HUANG Shuangying, XU Hui, MEI Huiting, HONG Yongping. Effects of Different Exercise Types on Fall Efficacy in the Elderly: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(06): 741-751. |
| [12] | ZHONG Lanfang, YU Xinyu, PI Zheyu, LI Bin. Drug-induced Cardiotoxicity in the Chinese Population: Current Analysis and Considerations [J]. Chinese General Practice, 2026, 29(06): 767-776. |
| [13] | CHEN Xiaoying, ZHU Xuebo, CHEN Yue. Research on the Mechanism Influencing Professional Identity of Rural Targeted-admission Medical Students Based on Social Cognitive Career Theory [J]. Chinese General Practice, 2026, 29(04): 530-537. |
| [14] | ZENG Minghui, KUAI Wentao, CHEN Lin, HAN Jiaxin, XU Lianxin, GE Liying, DAI Rongrong, MI Yuqiang, XU Liang. Effect of Type 2 Diabetes Mellitus on the Efficacy of Nucleoside (Acid) Analogues in the Treatment of Chronic Hepatitis B [J]. Chinese General Practice, 2025, 28(35): 4414-4420. |
| [15] | Expert Panel of the National Key R&D Program "Research on the Effects and Mechanisms of Multiple Types of Physical Stimulation on Body Function", Brain Function Detection and Regulation Rehabilitation Professional Committee of Chinese Association of Rehabilitation Medicine, Cerebral Small Vessel Disease Professional Committee of Beijing Neurology Association. Expert Consensus on the Effects and Efficacy Evaluation of Non-invasive Neuromodulation in Elders with Disability and Dementia [J]. Chinese General Practice, 2025, 28(34): 4258-4281. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||